

Reviewers for 1992

We wish to acknowledge the important assistance we have received from many scientists, who, along with the Editorial Board, have evaluated manuscripts submitted for publication during 1992. All outside reviewers are listed in the December issue of *Psychiatry Research* (Volume 44, Number 3, 1992).

Author Index for 1992

- Abbruzzese, M. 45:115
Adams, R.N. 45:203
Agartz, I. 45:139
Aigner, T.G. 45:153
Alliger, R. 45:33
Amass, L. 45:15
Anderer, P. 45:79
Andreasen, N.C. 45:33
Arndt, S. 45:33
Ashtari, M. 45:1
Baldwin, R.M. 45:67
Barbanjo, M.J. 45:79
Berman, K.F. 45:187
Bird, E.D. 45:203
Bjurling, P. 45:215
Bogerts, B. 45:1
Bossuyt, A. 45:227
Bossuyt-Piron, C. 45:227
Charney, D.S. 45:67
Cohen, G. 45:33
Cohen, R.M. 45:153
Colombo, C. 45:115
Cooper, J.E. 45:123
Coppola, R. 45:105
Coppola, R. 45:187
Costa, D.C. 45:143
D'haenen, H. 45:215
Degreef, G. 45:1
Dey, H.M. 45:67
Doudet, D.J. 45:153
Ebert, D. 45:239
Ehrhardt, J. 45:33
Ell, P.G. 45:143
Fairbanks, L.A. 45:177
Falkai, P. 45:1
Feistel, H. 45:239
Ford, R.A. 45:209
George, M.S. 45:143
Germine, M. 45:67
Gijsemans, M. 45:227
Gleason, R.P. 45:25
Goddard, A.W. 45:67
Greve, B. 45:1
Guze, B.H. 45:169
Guze, B.H. 45:177
Harrison, G. 45:123
Hartvig, P. 45:215
Heninger, G.R. 45:67
Hoffer, P.B. 45:67
Innis, R.B. 45:67
Inubushi, T. 45:53
Jones, D.W. 45:187
Karson, C.N. 45:95
Kaschka, W. 45:239
Kato, T. 45:53
Kaufman, L. 45:227
Kihlberg, T. 45:215
Komoroski, R.A. 45:95
Kuan, J. 45:33
Långström, B. 45:215
Lantos, G. 45:1
Lencz, T. 45:123
Lewis, S.W. 45:209
Lieberman, J. 45:1
Livian, S. 45:115
Locatelli, M. 45:115
Lundqvist, H. 45:215
Mandelkern, M.A. 45:177
Mareenco, S. 45:187
Marions, O. 45:139
McLellan, C.A. 45:153
Medley, I. 45:123
Mendelson, J.H. 45:15
Mertens, J. 45:227
Min, C.A. 45:177
Mohanakrishnan, P. 45:95
Nardin, R. 45:15
Newman, F. 45:105
Newton, J.E.O. 45:95
Oke, A.F. 45:203
Pawluczyk, S. 45:25
Pollock, V.E. 45:25
Putz, C. 45:203
Raine, A. 45:123
Rebring, L. 45:215
Reveley, A. 45:209
Reynolds, G.P. 45:123
Reynolds, L.M. 45:123

- Ring, H.A. 45:143
Robertson, M.M. 45:143
Ronchi, P. 45:115
Sääf, J. 45:139
Saletu, B. 45:79
Scarone, S. 45:115
Schneider, L.S. 45:25
Scotti, G. 45:115
Seibyl, J.P. 45:67
Semlitsch, H.V. 45:79
Sheard, C. 45:123
Small, G.W. 45:177
Smeraldi, E. 45:115
Smith, E.O. 45:67
Sprigg, J. 45:95
Stein, M.B. 45:105
Stern, C.E. 45:177
Syed, G.M.S. 45:209
Szuba, M.P. 45:169
Takahashi, S. 45:53
Tedroff, J. 45:215
Teoh, S.K. 45:15
Toone, B.K. 45:209
Trettau, J.R. 45:105
Trimble, M.R. 45:143
Uhde, T.W. 45:105
Wahlund, L.-O. 45:139
Weinberger, D.R. 45:187
Wetterberg, L. 45:139
Woods, B.T. 45:15
Woods, S.W. 45:67
Yuh, W.T.C. 45:33
Zemansky, M.F. 45:25
Zoghbi, S.S. 45:67

Subject Index for 1992

- Affective disorder**
age, leukoencephalopathy, 45:159
age, MRI, 45:159
bipolar subtype, lithium-7 brain concentration, 45:53
bipolar subtype, MRI spectroscopy, 45:53
ketanserin, serotonin₂ receptor, 45:227
ketanserin, SPECT, 45:227
leukoencephalopathy, age, 45:159
leukoencephalopathy, MRI, 45:159
lithium-7 brain concentration, bipolar subtype, 45:53
lithium-7 brain concentration, MRI spectroscopy, 45:53
MRI, age, 45:159
MRI, leukoencephalopathy, 45:159
MRI spectroscopy, bipolar subtype, 45:53
MRI spectroscopy, lithium-7 brain concentration, 45:53
serotonin₂ receptor, ketanserin, 45:227
serotonin₂ receptor, SPECT, 45:227
SPECT, ketanserin, 45:227
SPECT, serotonin₂ receptor, 45:227
- Age**
affective disorder, leukoencephalopathy, 45:159
affective disorder, MRI, 45:159
leukoencephalopathy, affective disorder, 45:159
leukoencephalopathy, MRI, 45:159
MRI, affective disorder, 45:159
MRI, leukoencephalopathy, 45:159
- Alcoholism**
electroencephalography, topographic mapping, 45:25
topographic mapping, electro-encephalography, 45:25
- Benzodiazepines**
iomazenil, normal controls, 45:67
iomazenil, occipital lobes, 45:67
iomazenil, SPECT, 45:67
normal controls, iomazenil, 45:67
normal controls, occipital lobes, 45:67
normal controls, SPECT, 45:67
occipital lobes, iomazenil, 45:67
occipital lobes, normal controls, 45:67
occipital lobes, SPECT, 45:67
SPECT, iomazenil, 45:67
SPECT, normal controls, 45:67
SPECT, occipital lobes, 45:67
- Blood flow**
catatonic syndrome, temporal lobe, 45:239
schizophrenia, catatonic syndrome, 45:239
- Blood flow continued**
schizophrenia, SPECT, 45:239
schizophrenia, temporal lobe, 45:239
SPECT, catatonic syndrome, 45:239
SPECT, schizophrenia, 45:239
SPECT, temporal lobe, 45:239
temporal lobe, catatonic syndrome, 45:239
temporal lobe, schizophrenia, 45:239
temporal lobe, SPECT, 45:239
- Caffeine**
electroencephalography, panic disorder, 45:105
panic disorder, electroencephalography, 45:105
panic disorder, topographic mapping, 45:105
topographic mapping, panic disorder, 45:105
- Caudate nucleus**
MRI, obsessive-compulsive disorder, 45:115
obsessive-compulsive disorder, MRI, 45:115
- Cavum septum pellucidum**
MRI, schizophrenia, 45:1
post-mortem studies, schizophrenia, 45:1
schizophrenia, MRI, 45:1
schizophrenia, post-mortem studies, 45:1
- Cerebrospinal fluid**
image processing, MRI, 45:33
image processing, segmentation methodology, 45:33
MRI, image processing, 45:33
MRI, segmentation methodology, 45:33
segmentation methodology, image processing, 45:33
segmentation methodology, MRI, 45:33
- Cocaine**
heroin, MRI, 45:15
MRI, heroin, 45:15
MRI, substance abuse, 45:15
substance abuse, MRI, 45:15
- Computed tomography**
frontal lobe, schizophrenia, 45:209
frontal lobe, SPECT, 45:209
frontal lobe, ventricular size, 45:209
schizophrenia, frontal lobe, 45:209
schizophrenia, SPECT, 45:209
schizophrenia, ventricular size, 45:209
SPECT, frontal lobe, 45:209
SPECT, schizophrenia, 45:209
SPECT, ventricular size, 45:209
ventricular size, frontal lobe, 45:209
ventricular size, schizophrenia, 45:209
ventricular size, SPECT, 45:209
- DOPA-F¹⁸**
MPTP, PET, 45:153
MPTP, primates, 45:153

- DOPA-F¹⁸** continued
 PET, MPTP, 45:153
 PET, primates, 45:153
 primates, MPTP, 45:153
 primates, PET, 45:153
- Dopamine**
 Huntington's disease, neuroleptics, 45:203
 Huntington's disease, post-mortem study, 45:203
 Huntington's disease, schizophrenia, 45:203
 Huntington's disease, thalamus, 45:203
 neuroleptics, Huntington's disease, 45:203
 neuroleptics, post-mortem study, 45:203
 neuroleptics, schizophrenia, 45:203
 neuroleptics, thalamus, 45:203
 post-mortem study, Huntington's disease, 45:203
 post-mortem study, neuroleptics, 45:203
 post-mortem study, schizophrenia, 45:203
 post-mortem study, thalamus, 45:203
 schizophrenia, Huntington's disease, 45:203
 schizophrenia, neuroleptics, 45:203
 schizophrenia, post-mortem study, 45:203
 schizophrenia, thalamus, 45:203
 thalamus, Huntington's disease, 45:203
 thalamus, neuroleptics, 45:203
 thalamus, post-mortem study, 45:203
 thalamus, schizophrenia, 45:203
- Electroencephalography**
 alcoholism, topographic mapping, 45:25
 artifact elimination, topographic mapping, 45:79
 caffeine, panic disorder, 45:105
 caffeine, topographic mapping, 45:105
 panic disorder, caffeine, 45:105
 panic disorder, topographic mapping, 45:105
 topographic mapping, alcoholism, 45:25
 topographic mapping, artifact elimination, 45:79
 topographic mapping, caffeine, 45:105
 topographic mapping, panic disorder, 45:105
- Fluoxetine**
 MR spectroscopy, neuroleptics, 45:95
 MR spectroscopy, schizophrenia, 45:95
 MR spectroscopy, trifluoperazine, 45:95
 neuroleptics, MR spectroscopy, 45:95
 neuroleptics, schizophrenia, 45:95
 schizophrenia, MR spectroscopy, 45:95
 schizophrenia, neuroleptics, 45:95
 schizophrenia, trifluoperazine, 45:95
 trifluoperazine, MR spectroscopy, 45:95
 trifluoperazine, schizophrenia, 45:95
- Frontal lobes**
 computed tomography, schizophrenia, 45:209
- Frontal lobes** continued
 computed tomography, SPECT, 45:209
 computed tomography, ventricular size, 45:209
 hydroxytryptophan-C¹¹, PCPA, 45:215
 hydroxytryptophan-C¹¹, PET, 45:215
 MRI, neuropsychological tests, 45:123
 MRI, schizophrenia, 45:123
 MRI, Wisconsin Card Sort Test, 45:123
 neuropsychological tests, MRI, 45:123
 neuropsychological tests, schizophrenia, 45:123
 obsessive-compulsive disorder, SPECT, 45:143
 obsessive-compulsive disorder, Tourette's syndrome, 45:143
 PCPA, hydroxytryptophan-C¹¹, 45:215
 PCPA, PET, 45:215
 PET, hydroxytryptophan-C¹¹, 45:215
 PET, PCPA, 45:215
 schizophrenia, computed tomography, 45:209
 schizophrenia, MRI, 45:123
 schizophrenia, neuropsychological tests, 45:123
 schizophrenia, SPECT, 45:209
 schizophrenia, ventricular size, 45:209
 schizophrenia, Wisconsin Card Sort Test, 45:123
 SPECT, computed tomography, 45:209
 SPECT, obsessive-compulsive disorder, 45:143
 SPECT, schizophrenia, 45:209
 SPECT, Tourette's syndrome, 45:143
 SPECT, ventricular size, 45:209
 Tourette's syndrome, obsessive-compulsive disorder, 45:143
 Tourette's syndrome, SPECT, 45:143
 ventricular size, computed tomography, 45:209
 ventricular size, schizophrenia, 45:209
 ventricular size, SPECT, 45:209
 Wisconsin Card Sort Test, MRI, 45:123
 Wisconsin Card Sort Test, schizophrenia, 45:123
- Heroin**
 cocaine, MRI, 45:15
 MRI, cocaine, 45:15
 MRI, substance abuse, 45:15
 substance abuse, MRI, 45:15
- Huntington's disease**
 dopamine, neuroleptics, 45:203
 dopamine, post-mortem study, 45:203
 dopamine, schizophrenia, 45:203
 dopamine, thalamus, 45:203
 neuroleptics, dopamine, 45:203
 neuroleptics, post-mortem study, 45:203
 neuroleptics, schizophrenia, 45:203
 neuroleptics, thalamus, 45:203

- Huntington's disease** continued
 post-mortem study, dopamine, 45:203
 post-mortem study, neuroleptics, 45:203
 post-mortem study, schizophrenia, 45:203
 post-mortem study, thalamus, 45:203
 schizophrenia, dopamine, 45:203
 schizophrenia, neuroleptics, 45:203
 schizophrenia, post-mortem study, 45:203
 schizophrenia, thalamus, 45:203
 thalamus, dopamine, 45:203
 thalamus, neuroleptics, 45:203
 thalamus, post-mortem study, 45:203
 thalamus, schizophrenia, 45:203
- 5-Hydroxytryptophan**
 frontal lobe, PCPA, 45:215
 frontal lobe, PET, 45:215
 PCPA, frontal lobe, 45:215
 PCPA, PET, 45:215
 PET, frontal lobe, 45:215
 PET, PCPA, 45:215
- Image processing**
 cerebrospinal fluid, MRI, 45:33
 cerebrospinal fluid, segmentation methodology, 45:33
 MRI, cerebrospinal fluid, 45:33
 MRI, segmentation methodology, 45:33
 segmentation methodology, cerebrospinal fluid, 45:33
 segmentation methodology, MRI, 45:33
- Iomazenil**
 benzodiazepine receptor ligand, normal controls, 45:67
 benzodiazepine receptor ligand, occipital lobes, 45:67
 benzodiazepine receptor ligand, SPECT, 45:67
 normal controls, benzodiazepine receptor ligand, 45:67
 normal controls, occipital lobes, 45:67
 normal controls, SPECT, 45:67
 occipital lobes, benzodiazepine receptor ligand, 45:67
 occipital lobes, normal controls, 45:67
 occipital lobes, SPECT, 45:67
 SPECT, benzodiazepine receptor ligand, 45:67
 SPECT, normal controls, 45:67
 SPECT, occipital lobes, 45:67
- Ketanserin**
 affective disorder, serotonin₂ receptor, 45:227
 affective disorder, SPECT, 45:227
 serotonin₂ receptor, affective disorder, 45:227
 serotonin₂ receptor, SPECT, 45:227
 SPECT, affective disorder, 45:227
 SPECT, serotonin₂ receptor, 45:227
- Leukoencephalopathy**
 affective disorder, age, 45:159
 affective disorder, MRI, 45:159
 age, affective disorder, 45:159
 age, MRI, 45:159
 MRI, affective disorder, 45:159
 MRI, age, 45:159
- Lithium**
 affective disorder, MRI spectroscopy, 45:53
 bipolar subtype, MRI spectroscopy, 45:53
 MRI spectroscopy, affective disorder, 45:53
 MRI spectroscopy, bipolar subtype, 45:53
MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine)
 DOPA-F¹⁸, PET, 45:153
 DOPA-F¹⁸, primates, 45:153
 PET, DOPA-F¹⁸, 45:153
 PET, primates, 45:153
 primates, DOPA-F-18, 45:153
 primates, PET, 45:153
- MRI** (magnetic resonance imaging)
 affective disorder, age, 45:159
 affective disorder, leukoencephalopathy, 45:159
 age, affective disorder, 45:159
 age, leukoencephalopathy, 45:159
 caudate nucleus, obsessive-compulsive disorder, 45:115
 cavum septum pellucidum, post-mortem studies, 45:1
 cavum septum pellucidum, schizophrenia, 45:1
 cerebrospinal fluid, imageprocessing, 45:33
 cerebrospinal fluid, segmentation methodology, 45:33
 cocaine, heroin, 45:15
 frequency of brain pathology, psychiatric patients, 45:139
 frontal lobe, neuropsychological tests, 45:123
 frontal lobe, schizophrenia, 45:123
 frontal lobe, Wisconsin Card Sort Test, 45:123
 heroin, cocaine, 45:15
 image processing, cerebrospinal fluid, 45:33
 image processing, segmentation methodology, 45:33
 leukoencephalopathy, affective disorder, 45:159
 leukoencephalopathy, age, 45:159
 neuropsychological tests, frontal lobe, 45:123
 neuropsychological tests, schizophrenia, 45:123
 obsessive-compulsive disorder, caudate nucleus, 45:115
 post-mortem studies, cavum septum

- MRI** continued
 pellucidum, 45:1
 post-mortem studies, schizophrenia, 45:1
 psychiatric patients, frequency of brain pathology, 45:139
 schizophrenia, cavum septum pellucidum, 45:1
 schizophrenia, frontal lobe, 45:123
 schizophrenia, neuropsychological tests, 45:123
 schizophrenia, post-mortem studies, 45:1
 schizophrenia, Wisconsin Card Sort Test, 45:123
 segmentation methodology, cerebrospinal fluid, 45:33
 segmentation methodology, image processing, 45:33
 substance abuse, 45:15
 Wisconsin Card Sort Test, frontal lobe, 45:123
 Wisconsin Card Sort Test, schizophrenia, 45:123
MR (magnetic resonance) spectroscopy
 affective disorder, lithium-7 brain concentration, 45:53
 bipolar subtype, lithium-7 brain concentration, 45:53
 fluoxetine, neuroleptics, 45:95
 fluoxetine, schizophrenia, 45:95
 fluoxetine, trifluoperazine, 45:95
 lithium-7 brain concentration, affective disorder, 45:53
 lithium-7 brain concentration, bipolar subtype, 45:53
 neuroleptics, fluoxetine, 45:95
 neuroleptics, schizophrenia, 45:95
 schizophrenia, fluoxetine, 45:95
 schizophrenia, neuroleptics, 45:95
 schizophrenia, trifluoperazine, 45:95
 trifluoperazine, fluoxetine, 45:95
 trifluoperazine, schizophrenia, 45:95
Neuroleptics
 dopamine, Huntington's disease, 45:203
 dopamine, post-mortem study, 45:203
 dopamine, schizophrenia, 45:203
 dopamine, thalamus, 45:203
 fluoxetine, trifluoperazine, 45:95
 Huntington's disease, dopamine, 45:203
 Huntington's disease, post-mortem study, 45:203
 Huntington's disease, schizophrenia, 45:203
 Huntington's disease, thalamus, 45:203
MR spectroscopy, schizophrenia, 45:95
MR spectroscopy, trifluoperazine, 45:95
 post-mortem study, dopamine, 45:203
 post-mortem study, Huntington's disease, 45:203
Neuroleptics continued
 post-mortem study, schizophrenia, 45:203
 post-mortem study, thalamus, 45:203
 schizophrenia, dopamine, 45:203
 schizophrenia, Huntington's disease, 45:203
 schizophrenia, MR spectroscopy, 45:95
 schizophrenia, post-mortem study, 45:203
 schizophrenia, thalamus, 45:203
 schizophrenia, trifluoperazine, 45:95
 thalamus, dopamine, 45:203
 thalamus, Huntington's disease, 45:203
 thalamus, post-mortem study, 45:203
 thalamus, schizophrenia, 45:203
 trifluoperazine, fluoxetine, 45:95
 trifluoperazine, MR spectroscopy, 45:95
 trifluoperazine, schizophrenia, 45:95
Neuropsychological tests
 frontal lobe, MRI, 45:123
 frontal lobe, schizophrenia, 45:123
 frontal lobe, Wisconsin Card Sort Test, 45:123
 MRI, frontal lobe, 45:123
 MRI, schizophrenia, 45:123
 MRI, Wisconsin Card Sort Test, 45:123
 schizophrenia, frontal lobe, 45:123
 schizophrenia, MRI, 45:123
 schizophrenia, Wisconsin Card Sort Test, 45:123
 Wisconsin Card Sort Test, frontal lobe, 45:123
 Wisconsin Card Sort Test, MRI, 45:123
 Wisconsin Card Sort Test, schizophrenia, 45:123
Obsessive-compulsive disorder
 caudate nucleus, MRI, 45:115
 frontal lobe, SPECT, 45:143
 frontal lobe, Tourette's syndrome, 45:143
 MRI, caudate nucleus, 45:115
 SPECT, frontal lobe, 45:143
 SPECT, Tourette's syndrome, 45:143
 Tourette's syndrome, frontal lobe, 45:143
 Tourette's syndrome, SPECT, 45:143
Occipital lobe
 benzodiazepine receptor ligand, iomazenil, 45:67
 benzodiazepine receptor ligand, normal controls, 45:67
 benzodiazepine receptor ligand, SPECT, 45:67
 iomazenil, normal controls, 45:67
 iomazenil, SPECT, 45:67
 normal controls, benzodiazepine receptor ligand, 45:67
 normal controls, iomazenil, 45:67
 normal controls, SPECT, 45:67

Occipital lobe continued

- SPECT, benzodiazepine receptor ligand, 45:67
- SPECT, iomazenil, 45:67
- SPECT, normal controls, 45:67

Panic disorder

- caffeine, electroencephalography, 45:105
- caffeine, topographic mapping, 45:105
- electroencephalography, caffeine, 45:105
- topographic mapping, caffeine, 45:105
- PCPA (para-chlorophenylalanine)**
- frontal lobe, hydroxytryptophan-C¹¹, 45:215
- frontal lobe, PET, 45:215
- hydroxytryptophan-C¹¹, frontal lobe, 45:215
- hydroxytryptophan-C¹¹, PET, 45:215
- PET, frontolobe, 45:215
- PET, hydroxytryptophan-C¹¹, 45:215
- PET (positron emission tomography)**
- DOPA-F¹⁸, MPTP, 45:153
- DOPA-F¹⁸, primates, 45:153
- frontal lobe, hydroxytryptophan-C¹¹, 45:215
- frontal lobe, PCPA, 45:215
- hydroxytryptophan-C¹¹, frontal lobe, 45:215
- hydroxytryptophan-C¹¹, PCPA, 45:215
- MPTP, DOPA-F¹⁸, 45:153
- MPTP, primates, 45:153
- PCPA, frontolobe, 45:215
- PCPA, hydroxytryptophan-C¹¹, 45:215
- primates, DOPA-F¹⁸, 45:153
- primates, MPTP, 45:153
- region of interest methodology, reliability, 45:177

Primates

- DOPA-F¹⁸, MPTP, 45:153
- DOPA-F¹⁸, PET, 45:153
- MPTP, DOPA-F¹⁸, 45:153
- MPTP, PET, 45:153
- PET, DOPA-F¹⁸, 45:153
- PET, MPTP, 45:153

Schizophrenia

- blood flow, catatonic syndrome, 45:239
- blood flow, SPECT, 45:239
- blood flow, temporal lobe, 45:239
- catatonic syndrome, blood flow, 45:239
- catatonic syndrome, SPECT, 45:239
- catatonic syndrome, temporal lobe, 45:239
- cavum septum pellucidum, MRI, 45:1
- cavum septum pellucidum, post-mortem studies, 45:1
- computed tomography, frontal lobe, 45:209
- computed tomography, SPECT, 45:209
- computed tomography, ventricular size, 45:209
- dopamine, Huntington's disease, 45:203
- dopamine, neuroleptics, 45:203

Schizophrenia continued

- dopamine, post-mortem study, 45:203
- dopamine, thalamus, 45:203
- fluoxetine, MR spectroscopy, 45:95
- fluoxetine, neuroleptics, 45:95
- fluoxetine, trifluoperazine, 45:95
- frontal lobe, computed tomography, 45:209
- frontal lobe, MRI, 45:123
- frontal lobe, neuropsychological tests, 45:123
- frontal lobe, SPECT, 45:209
- frontal lobe, ventricular size, 45:209
- frontal lobe, Wisconsin Card Sort Test, 45:123
- Huntington's disease, dopamine, 45:203
- Huntington's disease, neuroleptics, 45:203
- Huntington's disease, post-mortem study, 45:203
- Huntington's disease, thalamus, 45:203
- MR spectroscopy, fluoxetine, 45:95
- MR spectroscopy, neuroleptics, 45:95
- MR spectroscopy, trifluoperazine, 45:95
- MRI, cavum septum pellucidum, 45:1
- MRI, frontal lobe, 45:123
- MRI, neuropsychological tests, 45:123
- MRI, post-mortem studies, 45:1
- MRI, Wisconsin Card Sort Test, 45:123
- neuroleptics, dopamine, 45:203
- neuroleptics, fluoxetine, 45:95
- neuroleptics, Huntington's disease, 45:203
- neuroleptics, MR spectroscopy, 45:95
- neuroleptics, post-mortem study, 45:203
- neuroleptics, thalamus, 45:203
- neuropsychological tests, frontal lobe, 45:123
- neuropsychological tests, MRI, 45:123
- post-mortem studies, cavum septum pellucidum, 45:1
- post-mortem studies, MRI, 45:1
- post-mortem study, dopamine, 45:203
- post-mortem study, Huntington's disease, 45:203
- post-mortem study, neuroleptics, 45:203
- post-mortem study, thalamus, 45:203
- SPECT, blood flow, 45:239
- SPECT, catatonic syndrome, 45:239
- SPECT, computed tomography, 45:209
- SPECT, frontal lobe, 45:209
- SPECT, temporal lobe, 45:239
- SPECT, ventricular size, 45:239
- temporal lobe, blood flow, 45:239
- temporal lobe, catatonic syndrome, 45:239
- temporal lobe, SPECT, 45:239
- thalamus, dopamine, 45:203
- thalamus, Huntington's disease, 45:203
- thalamus, neuroleptics, 45:203
- thalamus, post-mortem study, 45:203

- Schizophrenia** continued
 trifluoperazine, fluoxetine, 45:95
 trifluoperazine, MR spectroscopy, 45:95
 ventricular size, computed tomography, 45:209
 ventricular size, frontal lobe, 45:209
 ventricular size, SPECT, 45:209
 Wisconsin Card Sort Test, frontal lobe, 45:123
 Wisconsin Card Sort Test, MRI, 45:123
- Segmentation techniques**
 cerebrospinal fluid, image processing, 45:33
 cerebrospinal fluid, MRI, 45:33
 image processing, cerebrospinal fluid, 45:33
 image processing, MRI, 45:33
 MRI, cerebrospinal fluid, 45:33
 MRI, image processing, 45:33
- Serotonin**
 affective disorder, ketanserin, 45:227
 affective disorder, SPECT, 45:227
 ketanserin, affective disorder, 45:227
 ketanserin, SPECT, 45:227
 SPECT, affective disorder, 45:227
 SPECT, ketanserin, 45:227
- SPECT (single photon emission computed tomography)**
 affective disorder, ketanserin, 45:227
 affective disorder, serotonin₂ receptor, 45:227
 benzodiazepine receptor ligand, iomazenil, 45:67
 benzodiazepine receptor ligand, normal controls, 45:67
 benzodiazepine receptor ligand, occipital lobes, 45:67
 blood flow, xenon-133 vs. xenon-127, 45:187
 bloodflow, catatonic syndrome, 45:239
 bloodflow, schizophrenia, 45:239
 bloodflow, temporal lobe, 45:239
 catatonic syndrome, blood flow, 45:239
 catatonic syndrome, schizophrenia, 45:239
 catatonic syndrome, temporal lobe, 45:239
 computed tomography, frontal lobe, 45:239
 computed tomography, schizophrenia, 45:209
 computed tomography, ventricular size, 45:209
 frontal lobe, computed tomography, 45:209
 frontal lobe, obsessive-compulsive disorder, 45:143
 frontal lobe, schizophrenia, 45:209
 frontal lobe, Tourette's syndrome, 45:143
 frontal lobe, ventricular size, 45:209
 iomazenil, benzodiazepine receptor ligand, 45:67
 iomazenil, normal controls, 45:67
 iomazenil, occipital lobes, 45:67
- SPECT continued**
 ketanserin, affective disorder, 45:227
 ketanserin, serotonin₂ receptor, 45:227
 normal controls, benzodiazepine receptor ligand, 45:67
 normal controls, iomazenil, 45:67
 normal controls, occipital lobes, 45:67
 obsessive-compulsive disorder, frontal lobe, 45:143
 obsessive-compulsive disorder, Tourette's syndrome, 45:143
 occipital lobes, benzodiazepine receptor ligand, 45:67
 occipital lobes, iomazenil, 45:67
 occipital lobes, normal controls, 45:67
 schizophrenia, bloodflow, 45:239
 schizophrenia, catatonic syndrome, 45:239
 schizophrenia, computed tomography, 45:209
 schizophrenia, frontal lobe, 45:209
 schizophrenia, temporal lobe, 45:239
 schizophrenia, ventricular size, 45:209
 serotonin₂ receptor, affective disorder, 45:227
 serotonin₂ receptor, ketanserin, 45:227
 temporal lobe, bloodflow, 45:239
 temporal lobe, catatonic syndrome, 45:239
 temporal lobe, schizophrenia, 45:239
 Tourette's syndrome, frontal lobe, 45:143
 Tourette's syndrome, obsessive-compulsive disorder, 45:143
 ventricular size, computed tomography, 45:209
 ventricular size, frontolobe, 45:209
 ventricular size, schizophrenia, 45:209
 xenon-133 vs. xenon-127, blood flow, 45:187
- Substance abuse** (see also **Alcoholism**)
 cocaine, MRI, 45:15
 heroin, MRI, 45:15
 MRI, cocaine, 45:15
 MRI, heroin, 45:15
- Temporal lobe**
 blood flow, catatonic syndrome, 45:239
 blood flow, schizophrenia, 45:239
 blood flow, SPECT, 45:239
 catatonic syndrome, blood flow, 45:239
 catatonic syndrome, schizophrenia, 45:239
 catatonic syndrome, SPECT, 45:239
 schizophrenia, blood flow, 45:239
 schizophrenia, catatonic syndrome, 45:239
 schizophrenia, SPECT, 45:239
 SPECT, blood flow, 45:239
 SPECT, catatonic syndrome, 45:239
 SPECT, schizophrenia, 45:239
- Thalamus**
 dopamine, Huntington's disease, 45:203
 dopamine, neuroleptics, 45:203

Thalamus continued

dopamine, post-mortem study, 45:203
 dopamine, schizophrenia, 45:203
 Huntington's disease, dopamine, 45:203
 Huntington's disease, neuroleptics, 45:203
 Huntington's disease, post-mortem study,
 45:203
 Huntington's disease, schizophrenia, 45:203
 neuroleptics, dopamine, 45:203
 neuroleptics, Huntington's disease, 45:203
 neuroleptics, post-mortem study, 45:203
 neuroleptics, schizophrenia, 45:203
 post-mortem study, dopamine, 45:203
 post-mortem study, Huntington's disease,
 45:203
 post-mortem study, neuroleptics, 45:203
 post-mortem study, schizophrenia, 45:203
 schizophrenia, dopamine, 45:203
 schizophrenia, Huntington's disease, 45:203
 schizophrenia, neuroleptics, 45:203
 schizophrenia, post-mortem study, 45:203
Topographic mapping
 alcoholism, electroencephalography, 45:25
 artifact elimination, electroencephalography,
 45:79
 caffeine, electroencephalography, 45:105
 caffeine, panic disorder, 45:105
 electroencephalography, alcoholism, 45:25
 electroencephalography, artifact elimination,
 45:79
 electroencephalography, caffeine, 45:105
 electroencephalography, panic disorder,
 45:105
 panic disorder, caffeine, 45:105
 panic disorder, electroencephalography,
 45:105

Tourette's syndrome

frontal lobe, obsessive-compulsive disorder,
 45:143
 frontal lobe, SPECT, 45:143
 obsessive-compulsive disorder, frontal lobe,
 45:143
 obsessive-compulsive disorder, SPECT,
 45:143
 SPECT, frontal lobe, 45:143
 SPECT, obsessive-compulsive disorder,
 45:143

Trifluoperazine

fluoxetine, MR spectroscopy, 45:95
 fluoxetine, schizophrenia, 45:95
 MR spectroscopy, fluoxetine, 45:95
 MR spectroscopy, schizophrenia, 45:95
 schizophrenia, fluoxetine, 45:95
 schizophrenia, MR spectroscopy, 45:95

Ventricular size

computed tomography, frontal lobe, 45:209
 computed tomography, schizophrenia, 45:209
 computed tomography, SPECT, 45:209
 frontal lobe, computed tomography, 45:209
 frontal lobe, schizophrenia, 45:209
 frontal lobe, SPECT, 45:209
 schizophrenia, computed tomography, 45:209
 schizophrenia, frontal lobe, 45:209
 schizophrenia, SPECT, 45:209
 SPECT, computed tomography, 45:209
 SPECT, frontal lobe, 45:209
 SPECT, schizophrenia, 45:209
Xenon-133 vs. xenon-127
 blood flow, SPECT, 45:187
 resolution, SPECT
 SPECT, blood flow, 45:187